|
시장보고서
상품코드
1517285
2피스 빈 하드 캡슐 시장 : 원료(젤라틴, 히드록시프로파일메틸셀룰로오스, 전분, 풀루란), 크기, 최종사용자, 지역별 예측(-2032년)Global Two-Piece Empty Hard Capsule Market Research Report Information by Raw Material (Gelatin Hydroxypropyl Methylcellulose, Starch and Pullulan), By size, By End Users And by Region - Forecast Till 2032 |
||||||
2피스 빈 하드 캡슐 시장 규모는 2023년 11억 3,000만 달러, 2024년 12억 달러에서 예측 기간 동안 7.08%의 연평균 복합 성장률(CAGR)로 2032년에는 22억 3,000만 달러 규모로 성장할 것으로 예상됩니다.
2피스 빈 하드캡슐 시장은 주로 비감염성 질환(NCD)의 발병률 증가로 인해 빠르게 성장하고 있습니다. 세계보건기구(WHO)는 2023년 NCD로 인해 연간 4,100만 명이 사망할 것으로 추산하고 있으며, 이는 전 세계 사망원인의 74%를 차지합니다. 전 세계적으로 비만, 당뇨병, 심혈관 질환 등 질병의 유병률이 증가하고 의약품 및 건강 보조 식품의 사용이 증가함에 따라 빈 하드 캡슐에 대한 수요가 증가하고 있습니다.
캡슐은 삼키기 쉽고 약물의 맛을 감출 수 있어 환자의 복약 순응도, 특히 장기적인 치료 계획 측면에서 이점이 있습니다. 이는 환자 중심의 의약품 개발 방법이라는 큰 업계 트렌드와 잘 부합합니다.
지역적 전망
북미는 2022년 36.60%로 가장 큰 점유율을 차지할 것으로 예상되며, 예측 기간 동안 5.70%의 연평균 복합 성장률(CAGR)로 성장하여 2032년에는 7억 1,000만 달러 이상의 규모에 이를 것으로 예상됩니다. 반면, 아시아태평양은 같은 기간 동안 8.89%의 가장 높은 CAGR로 성장할 것으로 예상됩니다.
북미 2피스 빈 하드캡슐 시장은 꾸준한 성장이 예상되며 좋은 미래가 기다리고 있습니다. 의료 인프라에 대한 투자와 현대 의료에 대한 대중의 인식이 높아짐에 따라 시장이 더욱 확대될 것으로 예상됩니다.
세계의 2피스 빈 하드 캡슐(2-Piece Empty Hard Capsule) 시장을 조사했으며, 시장 정의와 개요, 시장 성장에 영향을 미치는 요인과 시장 기회 분석, 시장 규모 추이와 예측, 각종 부문별/지역별/주요 국가별 분석, 경쟁 환경, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
목차
제1장 시장 서론
제2장 시장 개요
제3장 조사 방법
제4장 시장 역학
- 성장 촉진요인
- 성장 억제요인
- 기회
제5장 시장 요인 분석
- 밸류체인 분석
- Porter의 Five Forces 분석
- COVID-19가 세계 2피스 빈 하드 캡슐 시장에 미치는 영향
- 2피스 빈 하드 캡슐의 평균 단가
- 2피스 빈 하드 캡슐의 HS코드
제6장 세계의 2피스 빈 하드 캡슐 시장 : 원료별
- 개요
- 젤라틴
- 하이드록시 프로파일 메틸 셀룰로오스(HPMC)
- 전분 및 플루란
제7장 세계의 2피스 빈 하드 캡슐 시장 : 사이즈별
- 개요
- SIZE "00" CAPSULES
- SIZE "0" CAPSULES
- SIZE "1" CAPSULES
- SIZE "2" CAPSULES
- 기타
제8장 세계의 2피스 빈 하드 캡슐 시장 : 최종사용자별
- 개요
- 제약회사
- 건강 및 영양
- 기타
제9장 세계의 2피스 빈 하드 캡슐 시장 : 지역별
- 세계
- 북미
- 유럽
- 아시아태평양
- 기타 지역
제10장 경쟁 구도
- 시장 점유율 분석
- 경쟁 대시보드
- 공개 기업 주식 개요
- 비교 분석 : 주요 기업 재무 데이터
- 주요 전개와 성장 전략
- 동남아시아 주요 기업 리스트
제11장 기업 개요
- CAPSCANADA
- ROXLOR
- GOERLICH PHARMA GMBH
- LONZA
- QUALICAPS
- SUHEUNG
- ACG
- HUNAN ER-KANG PHARMACEUTICAL CO. LTD.
- SHANXI GUANGSHENG MEDICINAL CAPSULE CO., LTD,
- BRIGHT PHARMA CAPS INC.
- SHANDONG HEALSEE CAPSULE LTD.
- GDL CAPSULE
- JIUJIANG ANGTAI CAPSULE CO., LTD.
- SHANXI JC BIOLOGICAL TECHNOLOGY CO
- HEALTHCAPS INDIA
Global Two-Piece Empty Hard Capsule Market Research Report Information by Raw Material (Gelatin Hydroxypropyl Methylcellulose (HPMC), Starch and Pullulan), By size (Size "00" capsules, Size "0" capsules, Size "1" capsules, Size "2" capsules, others), By End Users (Pharmaceutical Companies, Health & Nutrition, Others) And by Region (North America, Europe, Asia-Pacific, And Rest of The World) - Forecast Till 2032
Market Synopsis
The size of the two-piece empty hard capsule market was estimated at USD 1.13 billion in 2023 and is expected to increase at a compound yearly growth rate (CAGR) of 7.08% from USD 1.20 billion in 2024 to USD 2.23 billion by 2032.
The market for two-piece empty hard capsules is expanding rapidly, driven mostly by the rising incidence of non-communicable diseases (NCDs). The World Health Organization (WHO) estimates that noncommunicable diseases (NCDs) would kill 41 million people year in 2023, making up 74% of all deaths globally. The demand for empty hard capsules has increased as a result of the increased use of pharmaceutical and nutraceutical therapies due to the rising prevalence of disorders including obesity, diabetes, and cardiovascular diseases around the world. These capsules are effective drug delivery systems that make it easier to provide different formulations to treat the complicated issues related to non-communicable diseases. Pharmaceutical companies are using two-piece empty hard capsules to encapsulate a wide range of medicinal substances, taking advantage of their adaptability as healthcare systems worldwide attempt to control and cure these common chronic illnesses.
Because the capsules are easy to swallow and hide the taste of pharmaceuticals, they also have a benefit in terms of patient compliance, particularly in long-term treatment regimes. This fits well with the larger industry trend of drug development methodologies that are patient centric.
Insights on Market Segments
Based on raw material, the global Two-Piece Empty Hard capsule segmentation comprises pullulan, gelatin, hydroxypropyl methylcellulose (HPMC), and starch.
Size-based market segmentation for two-piece empty hard capsules comprises of capsules with a "00" size, "0" size, "1" size, "2" size, and other sizes.
The end-user segmentation of the two-piece empty hard capsule market includes pharmaceutical businesses, health and nutrition, and other categories.
RegionalPerspectives
With the biggest market share of 36.60% in 2022, the North American two-piece empty hard capsule market is expected to grow at a 5.70% CAGR to reach over USD 0.71 billion by 2032. Nonetheless, throughout the course of the projection period, Asia-Pacific is expected to develop at the highest CAGR of 8.89%.
The two-piece empty hard capsule market in North America has a good future ahead of it, with steady growth predicted. Further market expansion is anticipated because of investments in healthcare infrastructure and rising public awareness of modern medical treatments.
Due to rising healthcare costs, the prevalence of chronic diseases, and technological improvements, the Europe Two-Piece Empty Hard Capsule Market had the second-largest market share.
The market for two-piece empty hard capsules in the Asia-Pacific region is anticipated to develop at the quickest rate between 2024 and 2032 due to the region's high patient population, rise in chronic illnesses, and advantageous regulatory framework. The expansion of major companies in the Two-Piece Empty Hard Capsule Market into this area is also propelling the growth of the regional market.
Principal Players
Important Businesses CapsCanada (Canada), Roxlor (US), Goerlich Pharma GmbH (Europe), Lonza (Switzerland), Qualicaps (US), Suheung (South Korea), ACG (India), Hunan Er-Kang Pharmaceutical Co. Ltd (China), Shanxi Guangsheng Medicinal Capsule Co., Ltd (China), and Bright Pharma Caps (US) are some of the companies that sell two-piece empty hard capsules on the market.
TABLE OF CONTENTS
1 MARKET INTRODUCTION
2 MARKET INTRODUCTION
- 2.1 DEFINITION
- 2.2 SCOPE OF THE STUDY
- 2.3 RESEARCH OBJECTIVE
- 2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
- 3.1 OVERVIEW
- 3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
- 3.3 PURCHASED DATABASE:
- 3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
- 3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
- 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
- 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
- 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
- 3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TYPE
- 3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
- 3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
- 4.1 INTRODUCTION
- 4.2 DRIVERS
- 4.2.1 INCREASING PREVALENCE OF NON-COMMUNICABLE DISEASES .
- 4.2.2 GROWING DEMAND FOR NUTRACEUTICALS
- 4.2.3 ADVANCEMENTS IN CAPSULE TECHNOLOGY
- 4.3 RESTRAINTS
- 4.3.1 ALTERNATIVE DRUG DELIVERY FORMS
- 4.4 OPPORTUNITY
- 4.4.1 GROWING PREFERENCES TOWARDS PLANT BASED CAPSUELS
5 MARKET FACTOR ANALYSIS
- 5.1 VALUE CHAIN ANALYSIS
- 5.1.1 R&D AND DESIGNING
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION AND SALES
- 5.1.4 POST-SALES MONITORING
- 5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 INTENSITY OF RIVALRY
- 5.3 IMPACT OF COVID-19 ON THE GLOBAL TWO-PIECE EMPTY HARD CAPSULE MARKET
- 5.3.1 IMPACT ON RESEARCH AND DEVELOPMENT
- 5.3.2 IMPACT ON SUPPLY CHAIN
- 5.3.3 IMPACT ON PRICING
- 5.4 AVERAGE UNIT PRICE OF TWO PIECE EMPTY HARD GELATIN CAPSULE
- 5.5 HS CODE OF TWO PIECE EMPTY HARD GELATIN CAPSULE
6 GLOBAL TWO-PIECE EMPTY HARD CAPSULE MARKET, BY RAW MATERIAL
- 6.1 OVERVIEW
- 6.2 GELATIN
- 6.3 HYDROXYPROPYL METHYLCELLULOSE (HPMC)
- 6.4 STARCH AND PULLULAN
7 GLOBAL TWO-PIECE EMPTY HARD CAPSULE MARKET, BY SIZE
- 7.1 OVERVIEW
- 7.2 SIZE "00" CAPSULES
- 7.3 SIZE "0" CAPSULES
- 7.4 SIZE "1" CAPSULES
- 7.5 SIZE "2" CAPSULES
- 7.6 OTHERS
8 GLOBAL TWO-PIECE EMPTY HARD CAPSULE MARKET, BY END USER
- 8.1 OVERVIEW
- 8.2 PHARMACEUTICAL COMPANIES
- 8.3 HEALTH & NUTRITION
- 8.4 OTHERS
9 GLOBAL TWO-PIECE EMPTY HARD CAPSULE MARKET, BY REGION
- 9.1 GLOBAL
- 9.2 NORTH AMERICA
- 9.2.1 US
- 9.2.2 CANADA
- 9.3 EUROPE
- 9.3.1 GERMANY
- 9.3.2 FRANCE
- 9.3.3 UK
- 9.3.4 ITALY
- 9.3.5 SPAIN
- 9.3.6 REST OF EUROPE
- 9.4 ASIA-PACIFIC
- 9.4.1 CHINA
- 9.4.2 INDIA
- 9.4.3 JAPAN
- 9.4.4 AUSTRALIA
- 9.4.5 SOUTH KOREA
- 9.4.6 REST OF ASIA-PACIFIC
- 9.5 REST OF THE WORLD
- 9.5.1 MIDDLE EAST & AFRICA
- 9.5.2 SOUTH AMERICA
10 COMPETITIVE LANDSCAPE
- 10.1 INTRODUCTION
- 10.2 MARKET SHARE ANALYSIS, 2022
- 10.3 COMPETITOR DASHBOARD
- 10.4 PUBLIC PLAYERS STOCK SUMMARY
- 10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
- 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 10.6.1 EXPANSION
- 10.7 LIST OF KEY PLAYERS IN SEA REGION
- 10.7.1 INDONESIA
- 10.7.2 TAIWAN
- 10.7.3 VIETNAM
- 10.7.4 MALAYSIA
11 COMPANY PROFILES
- 11.1 CAPSCANADA
- 11.1.1 COMPANY OVERVIEW
- 11.1.2 FINANCIAL OVERVIEW
- 11.1.3 PRODUCTS OFFERED
- 11.1.4 KEY DEVELOPMENTS
- 11.1.5 SWOT ANALYSIS
- 11.1.6 KEY STRATEGIES
- 11.2 ROXLOR
- 11.2.1 COMPANY OVERVIEW
- 11.2.2 FINANCIAL OVERVIEW
- 11.2.3 PRODUCTS OFFERED
- 11.2.4 KEY DEVELOPMENTS
- 11.2.5 KEY STRATEGIES
- 11.3 GOERLICH PHARMA GMBH
- 11.3.1 COMPANY OVERVIEW
- 11.3.2 FINANCIAL OVERVIEW
- 11.3.3 PRODUCTS OFFERED
- 11.3.4 KEY DEVELOPMENTS
- 11.3.5 SWOT ANALYSIS
- 11.3.6 KEY STRATEGIES
- 11.4 LONZA
- 11.4.1 COMPANY OVERVIEW
- 11.4.2 FINANCIAL OVERVIEW
- 11.4.3 PRODUCTS OFFERED
- 11.4.4 KEY DEVELOPMENTS
- 11.4.5 SWOT ANALYSIS
- 11.4.6 KEY STRATEGIES
- 11.5 QUALICAPS
- 11.5.1 COMPANY OVERVIEW
- 11.5.2 FINANCIAL OVERVIEW
- 11.5.3 PRODUCTS OFFERED
- 11.5.4 KEY DEVELOPMENTS
- 11.5.5 SWOT ANALYSIS
- 11.5.6 KEY STRATEGIES
- 11.6 SUHEUNG
- 11.6.1 COMPANY OVERVIEW
- 11.6.2 FINANCIAL OVERVIEW
- 11.6.3 PRODUCTS OFFERED
- 11.6.4 KEY DEVELOPMENTS
- 11.6.5 KEY STRATEGIES
- 11.7 ACG
- 11.7.1 COMPANY OVERVIEW
- 11.7.2 FINANCIAL OVERVIEW
- 11.7.3 PRODUCTS OFFERED
- 11.7.4 KEY DEVELOPMENTS
- 11.7.5 SWOT ANALYSIS
- 11.7.6 KEY STRATEGIES
- 11.8 HUNAN ER-KANG PHARMACEUTICAL CO. LTD.
- 11.8.1 COMPANY OVERVIEW
- 11.8.2 FINANCIAL OVERVIEW
- 11.8.3 PRODUCTS OFFERED
- 11.8.4 KEY DEVELOPMENTS
- 11.8.5 KEY STRATEGIES
- 11.9 SHANXI GUANGSHENG MEDICINAL CAPSULE CO., LTD,
- 11.9.1 COMPANY OVERVIEW
- 11.9.2 FINANCIAL OVERVIEW
- 11.9.3 PRODUCTS OFFERED
- 11.9.4 KEY DEVELOPMENTS
- 11.9.5 SWOT ANALYSIS
- 11.9.6 KEY STRATEGIES
- 11.10 BRIGHT PHARMA CAPS INC.
- 11.10.1 COMPANY OVERVIEW
- 11.10.2 FINANCIAL OVERVIEW
- 11.10.3 PRODUCTS OFFERED
- 11.10.4 KEY DEVELOPMENTS
- 11.10.5 KEY STRATEGIES
- 11.11 SHANDONG HEALSEE CAPSULE LTD.
- 11.11.1 COMPANY OVERVIEW
- 11.11.2 FINANCIAL OVERVIEW
- 11.11.3 PRODUCTS OFFERED
- 11.11.4 KEY DEVELOPMENTS
- 11.11.5 SWOT ANALYSIS
- 11.11.6 KEY STRATEGIES
- 11.12 GDL CAPSULE
- 11.12.1 COMPANY OVERVIEW
- 11.12.2 FINANCIAL OVERVIEW
- 11.12.3 PRODUCTS OFFERED
- 11.12.4 KEY DEVELOPMENTS
- 11.12.5 SWOT ANALYSIS
- 11.12.6 KEY STRATEGIES
- 11.13 JIUJIANG ANGTAI CAPSULE CO., LTD.
- 11.13.1 COMPANY OVERVIEW
- 11.13.2 FINANCIAL OVERVIEW
- 11.13.3 PRODUCTS OFFERED
- 11.13.4 KEY DEVELOPMENTS
- 11.13.5 KEY STRATEGIES
- 11.14 SHANXI JC BIOLOGICAL TECHNOLOGY CO
- 11.14.1 COMPANY OVERVIEW
- 11.14.2 FINANCIAL OVERVIEW
- 11.14.3 PRODUCTS OFFERED
- 11.14.4 KEY DEVELOPMENTS
- 11.14.5 KEY STRATEGIES
- 11.15 HEALTHCAPS INDIA
- 11.15.1 COMPANY OVERVIEW
- 11.15.2 FINANCIAL OVERVIEW
- 11.15.3 PRODUCTS OFFERED
- 11.15.4 KEY DEVELOPMENTS
- 11.15.5 SWOT ANALYSIS
- 11.15.6 KEY STRATEGIES
